Evaluating the Radiosensitization Effect of Hydroxyapatite Nanoparticles on Human Breast Adenocarcinoma Cell Line and Fibroblast

Overview

Journal Iran J Med Sci

Publisher Shiraz University of Medical Sciences

Specialty General Medicine

Date 2020 Oct 16

PMID 33060880

Citations 1

Authors

Mitra Soleimani

Fatemeh Elmi

Seyyed Hossein Mousavie Anijdan

Maryam Mitra Elmi

Affiliations

Soon will be listed here.

Abstract

Background: Nanohydroxyapatite (nHAP) exhibit anti-proliferative effects on various cancer cells. However, to date, there are only a few studies on the radiosensitization effect of nHAP. The present study aimed to investigate the possible enhancement of the radiosensitization effect of nHAP on human breast adenocarcinoma cancer (MCF-7) and fibroblast.

Methods: nHAP was extracted from fish scales using the thermal alkaline method and characterized at Babol University of Medical Sciences (Babol, Iran) in 2017. The anti-proliferative and the radiosensitization effects of nHAP were investigated by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT), clonogenic assay, and apoptosis assay. MCF-7 cells and fibroblasts were incubated with different concentrations of nHAP and at different periods. The MTT solution was added and the absorbance was measured at 570 nm. The MCF-7 cells were exposed to 0, 1.5, 3.5, and 5 Gy X-ray irradiation and incubated for 10-14 days. The data were compared using the one-way analysis of variance (ANOVA) followed by the post hoc tests (Tukey's method).

Results: The results showed that nHAP significantly inhibited the growth of MCF-7 cells compared with controls (P<0.001), but the difference was not statistically significant for fibroblasts (P=0.686 at 400 µg/mL at 72 hours). After 48 hours, the proliferation of MCF-7 cells and fibroblasts was inhibited by about 81% and 34% at 400 µg/mL concentration, respectively. The radiosensitization enhancement factor for MCF-7 cells and fibroblasts at a dose of 3.5 Gy and 100 μg/mL concentration were 1.87 and 1.3, respectively.

Conclusion: nHAP can be considered as a breast cancer radiosensitization agent with limited damage to the surrounding healthy tissue.

Citing Articles

The Combined Anti-Tumor Efficacy of Bioactive Hydroxyapatite Nanoparticles Loaded with Altretamine.

Alghazwani Y, Venkatesan K, Prabahar K, El-Sherbiny M, Elsherbiny N, Qushawy M Pharmaceutics. 2023; 15(1).

PMID: 36678930 PMC: 9861632. DOI: 10.3390/pharmaceutics15010302.

References

Han Y, Li S, Cao X, Yuan L, Wang Y, Yin Y . Different inhibitory effect and mechanism of hydroxyapatite nanoparticles on normal cells and cancer cells in vitro and in vivo. Sci Rep. 2014; 4:7134. PMC: 4238015. DOI: 10.1038/srep07134. View

Tang W, Yuan Y, Liu C, Wu Y, Lu X, Qian J . Differential cytotoxicity and particle action of hydroxyapatite nanoparticles in human cancer cells. Nanomedicine (Lond). 2013; 9(3):397-412. DOI: 10.2217/nnm.12.217. View

Dey S, Das M, Balla V . Effect of hydroxyapatite particle size, morphology and crystallinity on proliferation of colon cancer HCT116 cells. Mater Sci Eng C Mater Biol Appl. 2014; 39:336-9. DOI: 10.1016/j.msec.2014.03.022. View

Shapiro C, Recht A . Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001; 344(26):1997-2008. DOI: 10.1056/NEJM200106283442607. View

Chauhan V, Jain R . Strategies for advancing cancer nanomedicine. Nat Mater. 2013; 12(11):958-62. PMC: 4120281. DOI: 10.1038/nmat3792. View

Chu S, Karri S, Ma Y, Feng D, Li Z . In vitro and in vivo radiosensitization induced by hydroxyapatite nanoparticles. Neuro Oncol. 2013; 15(7):880-90. PMC: 3688012. DOI: 10.1093/neuonc/not030. View

Qing F, Wang Z, Hong Y, Liu M, Guo B, Luo H . Selective effects of hydroxyapatite nanoparticles on osteosarcoma cells and osteoblasts. J Mater Sci Mater Med. 2012; 23(9):2245-51. DOI: 10.1007/s10856-012-4703-6. View

Nicotera P, Bellomo G, Orrenius S . Calcium-mediated mechanisms in chemically induced cell death. Annu Rev Pharmacol Toxicol. 1992; 32:449-70. DOI: 10.1146/annurev.pa.32.040192.002313. View

Shi Z, Huang X, Cai Y, Tang R, Yang D . Size effect of hydroxyapatite nanoparticles on proliferation and apoptosis of osteoblast-like cells. Acta Biomater. 2008; 5(1):338-45. DOI: 10.1016/j.actbio.2008.07.023. View

10.

Franken N, Rodermond H, Stap J, Haveman J, van Bree C . Clonogenic assay of cells in vitro. Nat Protoc. 2007; 1(5):2315-9. DOI: 10.1038/nprot.2006.339. View

11.

Chu S, Feng D, Ma Y, Li Z . Hydroxyapatite nanoparticles inhibit the growth of human glioma cells in vitro and in vivo. Int J Nanomedicine. 2012; 7:3659-66. PMC: 3414202. DOI: 10.2147/IJN.S33584. View

12.

Van Meerloo J, Kaspers G, Cloos J . Cell sensitivity assays: the MTT assay. Methods Mol Biol. 2011; 731:237-45. DOI: 10.1007/978-1-61779-080-5_20. View

13.

Chen L, McCrate J, Lee J, Li H . The role of surface charge on the uptake and biocompatibility of hydroxyapatite nanoparticles with osteoblast cells. Nanotechnology. 2011; 22(10):105708. PMC: 3144725. DOI: 10.1088/0957-4484/22/10/105708. View

14.

Shi X, Zhou K, Huang F, Wang C . Interaction of hydroxyapatite nanoparticles with endothelial cells: internalization and inhibition of angiogenesis in vitro through the PI3K/Akt pathway. Int J Nanomedicine. 2017; 12:5781-5795. PMC: 5557617. DOI: 10.2147/IJN.S140179. View

15.

Linam J, Yang L . Recent developments in radiosensitization. Anticancer Res. 2015; 35(5):2479-85. View

16.

Liu Z, Tang S, Ai Z . Effects of hydroxyapatite nanoparticles on proliferation and apoptosis of human hepatoma BEL-7402 cells. World J Gastroenterol. 2003; 9(9):1968-71. PMC: 4656654. DOI: 10.3748/wjg.v9.i9.1968. View

17.

Chen F, Zhang X, Hu X, Liu P, Zhang H . The effects of combined selenium nanoparticles and radiation therapy on breast cancer cells in vitro. Artif Cells Nanomed Biotechnol. 2017; 46(5):937-948. DOI: 10.1080/21691401.2017.1347941. View